Abstract
p19INK4d, a member of the INK4 family of cyclin-dependent kinase inhibitors, negatively regulates the proto-oncogenic cyclin D/CDK4(6) complexes whose ability to phosphorylate the retinoblastoma tumour suppressor (RB) promotes G1/S transition. In contrast to the related p16INK4a tumour suppressor, expression patterns of 19INK4d in human tissues and tumours remain unknown. As the RB pathway is commonly targeted in cancer, and mouse models suggest a role for p19INK4d in spermatogenesis, we examined the abundance and localization of p19INK4d in the human testis, both during normal development and at various stages of germ-cell tumour pathogenesis. Our data show that the p19INK4d protein is abundant in spermatocytes of normal human adult testes, whereas virtually no p19INK4d is detectable in testicular cancer, including the preinvasive carcinoma in situ stage. Together with the lack of p19INK4d in human foetal germ cells, these results support the concept of foetal origin of the testicular germ-cell tumours, and help better understand the emerging role of the RB pathway in spermatogenesis and tumorigenesis in the human testis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andrews PW. . 1998 APMIS 106: 158–167.
Bartek J, Bartkova J and Lukas J. . 1996 Curr. Opin. Cell Biol. 8: 805–814.
Bartek J, Bartkova J and Lukas J. . 1997 Exp. Cell Res. 237: 1–6.
Bartkova J, Lukas J, Strauss M and Bartek J. . 1998 Oncogene 17: 1027–1037.
Bartkova J, Rajpert-De Meyts E, Skakkebæk NE and Bartek J. . 1999 J. Pathol. 187: 573–581.
Bartkova J, Thullberg M, Rajpert-De Meyts E, Skakkebæk NE and Bartek J. . 2000 Int. J. Cancer 85: 370–375.
Bernards R. . 1997 Biochim. Biophys. Acta 1333: M33–M40.
Chan FKM, Zhang J, Cheng L, Shapiro DN and Winoto A. . 1995 Mol. Cell. Biol. 15: 2682–2688.
Chaubert P, Guillou L, Kurt A-M, Bertholet M-M, Metthez G, Leisinger H-J, Bosman F and Shaw P. . 1997 Am. J. Pathol. 151: 859–865.
Dieckmann K-P and Skakkebæk NE. . 1999 Int. J. Cancer. 83: 815–822.
Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L and Xiong Y. . 1998 Genes Develop. 12: 2899–2911.
Grigor KM. . 1993 Eur. Urol. 23: 93–103.
Grigor KM and Wylie CC. . 1998 APMIS 106: 221–224.
Guan K-L, Jenkins CW, Li Y, O'Keefe CL, Noh S, Wu X, Zariwala M, Matera AG and Xiong Y. . 1996 Mol. Biol. Cell 7: 57–70.
Hall M and Peters G. . 1996 Adv. Cancer Res. 68: 67–108.
Heidenreich A, Gaddipati JP, Moul JW and Srivastava S. . 1998 J. Urol. 159: 1725–1730.
Helin K. . 1998 Curr. Opin. Genet. Dev. 8: 28–35.
Hirai H, Roussel MF, Kato J, Ashmun RA and Sherr CJ. . 1995 Mol. Cell. Biol. 15: 2672–2681.
Houldsworth J, Reuter V, Bosl GJ and Chaganti RSK. . 1997 Cell Growth Differ. 8: 293–299.
Hustin J, Colette J and Franchimont P. . 1987 Int. J. Androl. 10: 29–35.
Jørgensen N, Rajpert-De Meyts E, Græm N, Müller J, Giwercman A and Skakkebæk NE. . 1995 Lab. Invest. 72: 223–231.
Mostofi FK, Sesterhenn IA and Davis CJ. . 1986 In: Germ-cell Tumours. Vol II. Jones WG, Ward AM and Anderson CK . (eds.). Pergamon: Oxford. pp. 1–23.
Oosterhuis JW and Looijenga LHJ. . 1993 Eur. Urol. 23: 245–250.
Rajpert-de Meyts E, Jørgensen N, Brøndum-Nielsen K, Müller J and Skakkebæk NE. . 1998 APMIS 106: 198–206.
Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP and Barbacid M. . 1999 Nature Genet. 22: 44–52.
Roussel MF. . 1999 Oncogene 18: 5311–5317.
Ruas M and Peters G. . 1998 Biochim. Biophys. Acta. 1378: F115–F1177.
Serrano M, Lee H-W, Chin L, Cordon Cardo C, Beach D and De Pinho RA. . 1996 Cell 85: 27–37.
Sherr CJ. . 1996 Science 274: 1672–1677.
Sherr CJ and Roberts JM. . 1999 Genes Dev. 13: 1501–1512.
Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, Eppig JJ, Bronson RT, Elledge SJ and Weinberg RA. . 1996 Nature 384: 470–474.
Skakkebæk NE, Berthelsen JG, Giwercman A and Müller J. . 1987 Int. J. Androl. 10: 19–28.
Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R and Slamon D. . 1991 Proc. Natl. Acad. Sci. USA 88: 6662–6666.
Thullberg M, Welcker M, Bartkova J, Kjerulff AA, Lukas J, Högberg J and Bartek J. . 2000 Hybridoma 19: 63–72.
Zindy F, Quelle DE, Roussel MF and Sherr CJ. . 1997 Oncogene 15: 203–211.
Zindy F, van Deursen J, Grosveld G, Sherr CJ and Roussel MF. . 2000 Mol. Cell. Biol. 20: 372–378.
Acknowledgements
We thank Drs Niels Jørgensen and Niels Græm for sections of foetal testes. This work was supported by grants from the Danish Cancer Society, the Danish Biotechnology Programme, and the Danish Medical Research Council.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bartkova, J., Thullberg, M., Meyts, ED. et al. Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis. Oncogene 19, 4146–4150 (2000). https://doi.org/10.1038/sj.onc.1203769
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203769
Keywords
This article is cited by
-
Hypermethylation of the 5′ CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis
British Journal of Cancer (2005)
-
Testicular germ-cell tumours in a broader perspective
Nature Reviews Cancer (2005)
-
Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours
Oncogene (2001)